Literature DB >> 9345028

Thrombopoietin is synthesized by bone marrow stromal cells.

A Guerriero1, L Worford, H K Holland, G R Guo, K Sheehan, E K Waller.   

Abstract

We have previously characterized stromal progenitor cells contained in fetal bone marrow by fluorescence-activated cell sorting (FACS) using the differential expression of CD34, CD38, and HLA-DR, and found that a small number were contained within the CD34(+) cell fraction. In the present study, the frequency of stromal progenitors in both the CD34+ and CD34- subpopulations from samples of fetal and adult bone marrow was approximately one in 5,000 of the mononuclear cell fraction. Using multiparameter single-cell sorting, one in 20 fetal bone marrow cells with the CD34+, CD38-, HLA-DR-, CDw90+ phenotype were clonogenic stromal progenitors, whereas greater than one in five single cells with the CD34-, CD38-, HLA-DR-, CDw90+ phenotype formed stromal cultures. We found that cultures initiated by hematopoietic and stromal progenitors contained within the CD34+ fraction of bone marrow cells formed mixed hematopoietic/stromal cell cultures that maintained the viability of the hematopoietic progenitor cells for 3 weeks in the absence of added hematopoietic cytokines. We characterized some of the hematopoietic cytokines synthesized by stromal cultures derived from either CD34+ or CD34- bone marrow cells using reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of interleukin-3 (IL-3), stem cell factor (SCF), CD34, Flt3/Flk2 ligand (FL), and thrombopoietin (TPO) mRNA sequences. We found ubiquitous expression of TPO mRNA in greater than 90% of stromal cultures initiated by either CD34+ or CD34- cells, and variable expression of SCF, FL, and CD34 mRNA. In particular, SCF and CD34 mRNA were detected only in stromal cultures initiated by CD34+ bone marrow cells, although the differences between CD34+ and CD34- stromal cells were not statistically significant. IL-3 mRNA was not found in any stromal cultures. An enzyme-linked immunosorbent assay (ELISA) of soluble SCF and TPO present in culture supernatants demonstrated that biologically significant amounts of protein were secreted by some cultured stromal cells: eight of 16 samples of conditioned media from stromal cultures initiated by fetal and adult bone marrow contained more than 32 pg/mL SCF (in the linear range of the ELISA), with a median value of 32 pg/mL (range, 9 to 230), while 13 of 24 samples of conditioned media had more than 16 pg/mL TPO (in the linear range of the ELISA), with a median of 37 pg/mL (range, 16 to 106). Our data indicate that stromal cultures initiated by single bone marrow cells can make FL, SCF, and TPO. Local production of early-acting cytokines and TPO by stromal cells may be relevant to the regulation of hematopoietic stem cell self-renewal and megakaryocytopoiesis in the bone marrow microenvironment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345028

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  The Impact of Mesenchymal Stem Cells on Differentiation of Hematopoietic Stem Cells.

Authors:  Mahshid Saleh; Karim Shamsasanjan; Aliakbar Movassaghpourakbari; Parvin Akbarzadehlaleh; Zahra Molaeipour
Journal:  Adv Pharm Bull       Date:  2015-09-19

Review 2.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Historical review: megakaryopoiesis and thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

4.  Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance.

Authors:  Matthew Decker; Juliana Leslie; Qingxue Liu; Lei Ding
Journal:  Science       Date:  2018-04-06       Impact factor: 47.728

5.  Mesenchymal stromal cells lower platelet activation and assist in platelet formation in vitro.

Authors:  Avital Mendelson; Ana Nicolle Strat; Weili Bao; Peter Rosston; Georgia Fallon; Sophie Ohrn; Hui Zhong; Cheryl Lobo; Xiuli An; Karina Yazdanbakhsh
Journal:  JCI Insight       Date:  2019-08-22

6.  Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin.

Authors:  M Yagi; K A Ritchie; E Sitnicka; C Storey; G J Roth; S Bartelmez
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

7.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Authors:  Sagar Lonial; Edmund K Waller; Paul G Richardson; Sundar Jagannath; Robert Z Orlowski; Cynthia R Giver; David L Jaye; Dixil Francis; Sara Giusti; Claire Torre; Bart Barlogie; James R Berenson; Seema Singhal; David P Schenkein; Dixie-Lee W Esseltine; Jessica Anderson; Hugh Xiao; Leonard T Heffner; Kenneth C Anderson
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

8.  Platelet-derived growth factor enhances granulopoiesis via bone marrow stromal cells.

Authors:  M Yang; K Li; A C Lam; P M Yuen; T F Fok; C N Chesterman; B H Chong
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

9.  Increased differentiation of dermal mast cells in mice lacking the Mpl gene.

Authors:  Barbara Ghinassi; Maria Zingariello; Fabrizio Martelli; Rodolfo Lorenzini; Alessandro M Vannucchi; Rosa Alba Rana; Mitsuo Nishikawa; Giovanni Migliaccio; John Mascarenhas; Anna Rita Migliaccio
Journal:  Stem Cells Dev       Date:  2009-09       Impact factor: 3.272

10.  Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?

Authors:  Mojibade N Hassan; Edmund K Waller
Journal:  Oncology (Williston Park)       Date:  2015-04       Impact factor: 2.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.